| Literature DB >> 24568717 |
Mashael Al-Ghamdi, Laila Al-Ayadhi, Afaf El-Ansary1.
Abstract
BACKGROUND: Exposures to environmental toxins are now thought to contribute to the development of autism spectrum disorder. Propionic acid (PA) found as a metabolic product of gut bacteria has been reported to mimic/mediate the neurotoxic effects of autism. Results from animal studies may guide investigations on human populations toward identifying environmental contaminants that produce or drugs that protect from neurotoxicity. Forty-eight young male Western Albino rats were used in the present study. They were grouped into six equal groups 8 rats each. The first group received a neurotoxic dose of buffered PA (250 mg/Kg body weight/day for 3 consecutive days). The second group received only phosphate buffered saline (control group). The third and fourth groups were intoxicated with PA as described above followed by treatment with either coenzyme Q (4.5 mg/kg body weight) or melatonin (10 mg/kg body weight) for one week (therapeutically treated groups). The fifth and sixth groups were administered both compounds for one week prior to PA (protected groups). Heat shock protein70 (Hsp70), Gamma amino-butyric acid (GABA), serotonin, dopamine, oxytocin and interferon γ-inducible protein 16 together with Comet DNA assay were measured in brain tissues of the six studied groups.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24568717 PMCID: PMC3996043 DOI: 10.1186/1471-2202-15-34
Source DB: PubMed Journal: BMC Neurosci ISSN: 1471-2202 Impact factor: 3.288
Mean ± S.D and independent t-test for HSP-70, GABA, serotonin, dopamine, oxytocin, and Interferon μ inducible protein 16 (IFI16) in neurointoxicated, Co Q protected and treated rat pups compared to healthy control
| Control | 8 | 10.563 ± 0.370 | | |
| PA | 8 | 9.400 ± 0.490 | 0.001a | |
| CoQ-Protected group | 6 | 10.050 ± 0.404 | 0.030a | |
| CoQ-treated group | 8 | 10.033 ± 0.427 | 0.029a | |
| Control | 8 | 109.100 ± 4.666 | | |
| PA | 8 | 67.183 ± 3.125 | 0.001a | |
| CoQ-Protected group | 6 | 95.417 ± 4.529 | 0.01a | |
| CoQ-treated group | 8 | 85.079 ± 4.832 | 0.01a | |
| Control | 8 | 0.073 ± 0.017 | | |
| PA | 8 | 0.047 ± 0.011 | 0.004a | |
| CoQ-Protected group | 6 | 0.095 ± 0.018 | 0.043a | |
| CoQ-treated group | 8 | 0.097 ± 0.018 | 0.033a | |
| Control | 8 | 136.250 ± 18.468 | | |
| PA | 8 | 106.875 ± 12.229 | 0.002a | |
| CoQ-Protected group | 6 | 169.167 ± 24.580 | 0.014a | |
| CoQ-treated group | 8 | 160.000 ± 22.583 | 0.051a | |
| Control | 8 | 89.750 ± 4.464 | | |
| PA | 8 | 84.500 ± 4.751 | 0.039a | |
| CoQ-Protected group | 6 | 95.667 ± 4.967 | 0.037a | |
| CoQ-treated group | 8 | 95.000 ± 3.742 | 0.038a | |
| Control | 8 | 833.750 ± 63.906 | | |
| PA | 8 | 768.750 ± 53.033 | 0.044a | |
| CoQ-Protected group | 6 | 931.667 ± 77.567 | 0.024a | |
| CoQ-treated group | 8 | 983.333 ± 60.222 | 0.001a |
aSignificant level between the studied groups compared to control when P < 0.05.
Mean ± S.D and independent t-test for HSP-70, GABA, serotonin, dopamine, oxytocin, and Interferon μ inducible protein 16 (IFI-16) in neurointoxicated, melatonin protected and treated rat pups compared to healthy control
| Control | 8 | 10.563 ± 0.370 | | |
| PA | 8 | 9.400 ± 0.490 | 0.001a | |
| Melatonin-protected group | 8 | 10.043 ± 0.454 | 0.030a | |
| Melatonin-treated group | 8 | 10.083 ± 0.445 | 0.048a | |
| Control | 8 | 109.100 ± 4.666 | | |
| PA | 8 | 67.183 ± 3.125 | 0.001a | |
| Melatonin-protected group | 8 | 83.160 ± 4.668 | 0.01a | |
| Melatonin-treated group | 8 | 75.144 ± 2.694 | 0.001a | |
| Control | 8 | 0.073 ± 0.017 | | |
| PA | 8 | 0.047 ± 0.011 | 0.004a | |
| Melatonin-protected group | 8 | 0.101 ± 0.019 | 0.011a | |
| Melatonin-treated group | 8 | 0.099 ± 0.019 | 0.016a | |
| Control | 8 | 136.250 ± 18.468 | | |
| PA | 8 | 106.875 ± 12.229 | 0.002a | |
| Melatonin-protected group | 8 | 173.125 ± 29.873 | 0.010a | |
| Melatonin-treated group | 8 | 164.375 ± 23.213 | 0.018a | |
| Control | 8 | 89.750 ± 4.464 | | |
| PA | 8 | 84.500 ± 4.751 | 0.039a | |
| Melatonin-protected group | 8 | 97.750 ± 8.714 | 0.037a | |
| Melatonin-treated group | 8 | 100.750 ± 6.409 | 0.001a | |
| Control | 8 | 833.750 ± 63.906 | | |
| PA | 8 | 768.750 ± 53.033 | 0.044a | |
| Melatonin-protected group | 8 | 921.250 ± 71.801 | 0.022a | |
| Melatonin-treated group | 8 | 922.500 ± 79.057 | 0.027a |
aSignificant level between the studied groups compared to control when P < 0.05.
Figure 1Percentage change ± S.D error bars of Hsp70, GABA, serotonin, dopamine, oxytocin, and IFI16 in PA-neurointoxicated, coenzyme Q and melatonin protected or treated rat pups compared to healthy control.
Tail Length (μm), Tail DNA% and Tail Moments in PA-intoxicated, Co Q or melatonin supplemented compared to control- healthy rat pups
| Tail Length (μm) | Control | 1.06 | 1.42 | 1.25 ± 0.16 | 0.001 |
| PA | 4.67 | 5.34 | 4.96 ± 0.28a | ||
| Melatonin-protected | 3.17 | 4.33 | 3.56 ± 0.55a | ||
| Melatonin-treated | 3.95 | 4.26 | 4.11 ± 0.13a | ||
| CoQ10-protected | 2.87 | 3.05 | 2.94 ± 0.08a | ||
| CoQ10-treated | 3.59 | 3.95 | 3.82 ± 0.16a | ||
| Tail DNA% | Control | 1.22 | 1.62 | 1.40 ± 0.17 | 0.001 |
| PA | 4.51 | 5.15 | 4.85 ± 0.27a | ||
| Melatonin-protected | 3.12 | 3.33 | 3.20 ± 0.09a | ||
| Melatonin-treated | 3.52 | 4.26 | 3.95 ± 0.33a | ||
| CoQ10-protected | 2.80 | 3.41 | 3.10 ± 0.25a | ||
| CoQ10-treated | 3.16 | 3.75 | 3.55 ± 0.28a | ||
| Tail Moments (Units) | Control | 1.42 | 2.15 | 1.76 ± 0.37 | 0.001 |
| PA | 21.96 | 25.78 | 24.07 ± 1.87a | ||
| Melatonin-protected | 10.18 | 13.67 | 11.39 ± 1.57a | ||
| Melatonin-treated | 15.00 | 17.79 | 16.20 ± 1.21a | ||
| CoQ10-protected | 8.09 | 9.81 | 9.11 ± 0.76a | ||
| CoQ10-treated | 11.33 | 14.83 | 13.58 ± 1.59a |
Table 3 describes the One-way ANOVA test between the Control, PPA, Melatonine + PA, PA + Melatonine, CO Q + PA and PA + CO Q groups in Tail Length (μm), Tail DNA% and Tail Moments (Units) groups and Dunnett test as multiple comparisons.
aSignificant level between the studied groups compared to control when P < 0.05.
Figure 2Photograph showing comet tailing in PA treated (II) together with the protective and therapeutic effects of melatonin and Co Q (III-VI) in rat brains compared to control (I).